GLYC GlycoMimetics Inc.

12.26
+0.15  (+1%)
Previous Close 12.11
Open 12.08
Price To Book 2.58
Market Cap 529251560
Shares 43,168,969
Volume 58,995
Short Ratio
Av. Daily Volume 219,540

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 4Q 2020.
Uproleselan (GMI-1271)
Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer
Phase 3 data due late-2Q 2019.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Phase 1 ongoing.
GMI-1271
Multiple myeloma
Proof of concept trial to be initiated 2H 2019.
GMI-1359
Hormone receptor positive metastatic breast cancer

Latest News

  1. GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
  2. Edited Transcript of GLYC earnings conference call or presentation 6-Mar-19 1:30pm GMT
  3. GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359
  4. GlycoMimetics to Present at Upcoming Investor Conferences
  5. GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019
  6. Did GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Sell Shares?
  7. GlycoMimetics Inc (GLYC) Q4 2018 Earnings Conference Call Transcript
  8. GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results
  9. GlycoMimetics, Inc. to Host Earnings Call
  10. GlycoMimetics Announces Transition Plan for Board of Directors
  11. GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019
  12. Detailed Research: Economic Perspectives on Waddell & Reed Financial, Kennametal, Automatic Data Processing, Trustmark, Eagle Bulk Shipping, and GlycoMimetics — What Drives Growth in Today's Competitive Landscape
  13. Here’s What We Think About GlycoMimetics, Inc.’s (NASDAQ:GLYC) CEO Pay
  14. GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates
  15. GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting
  16. GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018
  17. Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors
  18. 3 Top Biotech Stocks to Buy Right Now
  19. GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
  20. Edited Transcript of GLYC earnings conference call or presentation 2-Nov-18 12:30pm GMT